Top Markets
#1 DogBull DogBull +107.67%
#2 MarsCoin MarsCoin +53.34%
#3 Siacoin Siacoin +51.79%
#4 The Bitcoin Bull The Bitcoin Bull +33.48%
#5 ADO Protocol ADO Protocol +28.63%
#6 Ontology Gas Ontology Gas +17.65%
#7 UnifAI Network UnifAI Network +12.27%
#8 Cash Cat Cash Cat +11.74%
#9 Akedo Akedo +10.76%
#10 Apertum Apertum +10.14%
Coin of the day
DogBull DogBull
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
VectivBio Holding AG VectivBio Holding AG

VectivBio Holding AG

VECT
Clasificación en acciones #14767
VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to... VectivBio Holding AG is a clinical-stage biopharmaceutical firm committed to identifying, developing, and commercializing treatments for severe rare medical conditions. The company's primary therapeutic focus is apraglutide, a prolonged-acting synthetic peptide analog of glucagon-like peptide-2. This compound is currently in a Phase III clinical trial for individuals with short bowel syndrome-intestinal failure (SBS-IF), and is also being evaluated in a Phase II clinical trial for SBS-IF patients with colon-in-continuity anatomy. Furthermore, apraglutide is undergoing a Phase II clinical study for patients experiencing steroid-refractory gastrointestinal acute graft-versus-host disease (aGvHD). Founded in 2019, VectivBio's corporate headquarters are situated in Basel, Switzerland.
Precio por acción
$16.85
Última sincronización: 2023-07-07
Capitalización bursátil
$393.50M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
CH
Comercio VectivBio Holding AG (VECT)

Categoría

Healthcare
Ganancias de VectivBio Holding AG (VECT)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di VectivBio Holding AG, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de VectivBio Holding AG desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH